BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
53.25
+0.33 (0.62%)
Last updated: Jun 27, 2025
61.56%
Market Cap 22.39B
Revenue (ttm) 1.19B
Net Income (ttm) 138.06M
Shares Out 422.40M
EPS (ttm) 0.33
PE Ratio 161.85
Forward PE 85.48
Dividend 0.10 (0.18%)
Ex-Dividend Date Jun 23, 2025
Volume 975,189
Average Volume 14,513,352
Open 52.85
Previous Close 52.92
Day's Range 52.72 - 53.35
52-Week Range 22.82 - 60.24
Beta 0.16
RSI 49.95
Earnings Date Aug 22, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,151
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 189.17 million, a decrease of -6.57%.

Financial Statements

News

There is no news available yet.